4.5 Article

Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial

期刊

CARDIOVASCULAR DRUGS AND THERAPY
卷 -, 期 -, 页码 -

出版社

SPRINGER
DOI: 10.1007/s10557-022-07411-2

关键词

COVID-19; Remote ischaemic conditioning; Randomized controlled trial; Cytokine storm; Immunosuppression; Inflammatory cascade

资金

  1. Thompson Family Trust
  2. Hatter Cardiovascular InstituteUCL
  3. Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)
  4. SAMRC Self-Initiated Research Grant
  5. UCT Start-up Emerging Researcher Award (SERA)
  6. Edith Sorell's cardiovascular research fellowship
  7. Research Career Awards grant from the Brazilian National Research Council (CNPq) [304257/2021-4]
  8. Mancherje-Potash Foundation

向作者/读者索取更多资源

RIC did not reduce the hypercytokinaemia induced by COVID-19 or prevent clinical deterioration to critical care.
Purpose Patients hospitalized with COVID-19 may develop a hyperinflammatory, dysregulated cytokine storm that rapidly progresses to acute respiratory distress syndrome, multiple organ dysfunction, and even death. Remote ischaemic conditioning (RIC) has elicited anti-inflammatory and cytoprotective benefits by reducing cytokines following sepsis in animal studies. Therefore, we investigated whether RIC would mitigate the inflammatory cytokine cascade induced by COVID-19. Methods We conducted a prospective, multicentre, randomized, sham-controlled, single-blind trial in Brazil and South Africa. Non-critically ill adult patients with COVID-19 pneumonia were randomly allocated (1:1) to receive either RIC (intermittent ischaemia/reperfusion applied through four 5-min cycles of inflation (20 mmHg above systolic blood pressure) and deflation of an automated blood-pressure cuff) or sham for approximately 15 days. Serum was collected following RIC/sham administration and analyzed for inflammatory cytokines using flow cytometry. The endpoint was the change in serum cytokine concentrations. Participants were followed for 30 days. Results Eighty randomized participants (40 RIC and 40 sham) completed the trial. Baseline characteristics according to trial intervention were overall balanced. Despite downward trajectories of all cytokines across hospitalization, we observed no substantial changes in cytokine concentrations after successive days of RIC. Time to clinical improvement was similar in both groups (HR 1.66; 95% CI, 0.938-2.948, p 0.08). Overall RIC did not demonstrate a significant impact on the composite outcome of all-cause death or clinical deterioration (HR 1.19; 95% CI, 0.616-2.295, p = 0.61). Conclusion RIC did not reduce the hypercytokinaemia induced by COVID-19 or prevent clinical deterioration to critical care.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据